Status:
COMPLETED
Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung
Lead Sponsor:
Pfizer
Conditions:
Carcinoma, Non-small Cell
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will explore the safety and efficacy of the oral PanHER inhibitor PF-00299804 in patients with adenocarcinoma of the lung who are either non-smokers (\<100 cigarette, cigar or pipe lifetime...
Eligibility Criteria
Inclusion
- Advanced adenocarcinoma of lung, measurable disease
- Non-smoker, or former light (less than 10 pack years and stopped at least 15 years); OR
- patients with known EGFR activating mutation regardless of smoking status
- ECOG(Eastern Cooperative Oncology Group) 0-1.
- Cohort B (select sites only): patients with HER2 amplified or HER2 mutation-positive NSCLC; may have had prior therapy
Exclusion
- Active brain metastases
- Prior systemic therapy for advanced disease in Cohort A only. Cohort B can have had any number of prior lines of systemic therapy.
- known EGFR wild type NSCLC
Key Trial Info
Start Date :
March 11 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2015
Estimated Enrollment :
119 Patients enrolled
Trial Details
Trial ID
NCT00818441
Start Date
March 11 2009
End Date
April 30 2015
Last Update
January 8 2019
Active Locations (41)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, Irvine
Orange, California, United States, 92868-3298
2
Chao Family Comprehensive Cancer Center UC Irvine Medical Center
Orange, California, United States, 92868
3
Bay Area Cancer Research Group, LLC
Pleasant Hill, California, United States, 94523
4
Pacific Cancer Care
Salinas, California, United States, 93901